The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | ctDNA and liquid biopsies in HL
Sven Borchmann, MD, University of Cologne, Cologne, Germany, touches on the potential of circulating tumor DNA (ctDNA) and liquid biopsies as tools for monitoring response to treatment in patients with Hodgkin lymphoma (HL), as well as the next steps to better understand the role of these tools in stratifying patients response. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
